1921
Volume 94, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Millions of people cannot access good quality essential medicines they need for some of the world's worst diseases like malaria. The World Health Organization estimates that, in 2013, 198 million people became sick with malaria and 584,000 people died of the disease, while the Institute for Health Metrics Evaluation estimates that there were 164,929,872 cases of malaria in 2013 and 854,568 deaths in 2013. There are many attempts to model different aspects of the global burden of tropical diseases like malaria, but it is also important to measure success in averting malaria-related death and disability. This perspective proposes investing in a systematic effort to measure the benefits of health interventions for malaria along the lines of a model embodied in the Global Health Impact Index (global-health-impact.org).

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0409
2016-05-04
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/5/942.html?itemId=/content/journals/10.4269/ajtmh.15-0409&mimeType=html&fmt=ahah

References

  1. Nayyar GML, Breman JG, Herrington JE, , 2015. The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. Am J Trop Med Hyg 92 (Suppl 6): 27.[Crossref]
  2. WHO, 2014. Fact Sheet on the World Malaria Report 2014. Available at: http://www.who.int/malaria/media/world_malaria_report_2014/en/. Accessed November 8, 2015.
  3. GBD 2013 Mortality and Causes of Death Collaborators, 2015. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385: 117171.[Crossref]
  4. Medicines for Malaria Venture, 2015. Bridging the Data Gap: MMV Helps Build Robust Data on the African Antimalarials Market. Available at: http://www.mmv.org/about-us/achievements-challenges/challenges/bridging-data-gap. Accessed September 19, 2015.
  5. Bao L, , 2012. A new infectious disease model for estimating and projecting HIV/AIDS epidemics. Sex Transm Infect 88: i58i64.[Crossref]
  6. Breman JG, Mills A, Snow RW, Mulligan J, Lengeler C, Mendis K, Sharp B, Morel C, Marchesini P, White NJ, Steketee RW, Doumbo OK, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, , 2006. Conquering malaria. , eds. Disease Control Priorities in Developing Countries, 2nd edition. Washington, DC: World Bank, 413432.[Crossref]
  7. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, Jha P, Musgrove P, Chow J, Shahid-Salles S, Jamison DT, , 2006. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 367: 11931208.[Crossref]
  8. Frosch AEP, Venkatesan M, Laufer MK, , 2011. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar J 10: 116.[Crossref]
  9. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, , eds, 2006. Disease Control Priorities in Developing Countries, 2nd edition. Washington, DC: World Bank.
  10. John Snow, Inc., 2015. In Mozambique, Improved Supply Chain Reporting Means Better Access to Health Commodities. Boston, MA: John Snow, Inc. Available at: http://www.jsi.com/JSIInternet/Results/article/display.cfm?thisSection=Results&thisSectionTitle=Results&thisPage=stories&ctid=1030&cid=244&tid=20&id=1556. Accessed September 19, 2015.
  11. USAID, 2011. Guidelines for Managing the Malaria Supply Chain. USAID Deliver Project. Available at: http://deliver.jsi.com/dlvr_content/resources/allpubs/guidelines/GuidManaMalariaSC.pdf. Accessed September 1, 2015.
  12. USAID, 2015. Ensuring Sustained Availability of ACTs in Malawi through Improved Routine Logistics Reporting and Pipeline Monitoring. USAID Deliver Project. Available at: http://deliver.jsi.com/dlvr_content/resources/allpubs/logisticsbriefs/MalLogHigh_EnsurSustAvailACTsMalawi.pdf. Accessed September 1, 2015.
  13. Newton PN, Green MD, Mildenhall DC, Plançon A, Nettey H, Nyadong L, Hostetler DM, Swamidoss I, Harris GA, Powell K, Timmermans AE, Amin AA, Opuni SK, Barbereau S, Faurant C, Soong RCW, Faure K, Thevanayagam J, Fernandes P, Kaur H, Angus B, Stepniewska K, Guerin PJ, Fernández FM, , 2011. Poor quality vital anti-malarials in Africa: an urgent neglected public health priority. Malar J 10: 352.[Crossref]
  14. Herrington J, Hamburg M, Green M, Zaman MH, Kaur H, Yeung S, Leslie T, Mackey T, Hajjou M, Goodman C, Tabernero P, Newton P, Laxminarayan R, Attaran A, , 2015. The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. Am J Trop Med Hyg 92 (Suppl 6): 27. Available at: http://www.astmh.org/AJTMH_Fake_Drugs_Supplement/6542.htm. Accessed September 19, 2015.
  15. Taylor SM, Juliano JJ, , 2014. Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. J Infect Dis 210: 335337.[Crossref]
  16. Komatsu R, Korenromp EL, Low-Beer D, Watt C, Dye C, Steketee RW, Nahlen BL, Lyerla R, Garcia-Calleja JM, Cutler J, Schwartländer B, , 2010. Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis 10: 109.[Crossref]
  17. Sudoi RK, Githinji S, Nyandigisi A, Muturi A, Snow RW, Zurovac D, , 2012. The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya. Malar J 11: 37.[Crossref]
  18. Githinji S, Kigen S, Memusi D, Nyandigisi A, Mbithi AM, Wamari A, Muturi AN, Jagoe G, Barrington J, Snow RW, Zurovac D, , 2013. Reducing stock-outs of life saving malaria commodities using mobile phone text-messaging: SMS for Life study in Kenya. PLoS One 8: e54066.[Crossref]
  19. Kebede A, Woyessa A, Urga K, Messelle T, Jima D, , 2010. Policy brief on improving access to artemisinin-based combination therapies for malaria control in Ethiopia. Int J Technol Assess Health Care 26: 246249.[Crossref]
  20. Global Health Data Exchange, 2014. Global Burden of Disease Study 2010. Results by Cause 1990–2010. Seattle, WA: Institute for Health Metrics and Evaluation. Available at: http://ghdx.healthdata.org/record/global-burden-disease-study-2010-gbd-2010-results-cause-1990-2010. Accessed January 1, 2013.
  21. WHO, 2015. World Malaria Reports 2008–2014. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/malaria/publications/world_malaria_report/en/. Accessed September 1, 2015.
  22. UNICEF, 2015. Multiple Indicator Cluster Survey (MICS). Available at: http://mics.unicef.org/. Accessed September 26, 2015.
  23. Global Health Data Exchange, 2015. Global Burden of Disease Study 2013. Seattle, WA: Institute for Health Metrics and Evaluation. Available at: http://ghdx.healthdata.org/global-burden-disease-study-2013-gbd-2013-data-downloads. Accessed September 26, 2015.
  24. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle KE, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW, , 2015. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 526: 207211.[Crossref]
  25. Hassoun N, , 2015. The Extending Access Index: Promoting Global Health. Global Health Impact. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141374. Accessed September 19, 2015.
  26. Allmendinger T, Wernsdorfer W, , 1998. European patent no. EP1089961. Munich, Germany: European Patent Office.
  27. Novartis Global, 2011. The Novartis Malaria Initiative: Lessons from a Dramatic Decade. Available at: http://www.malaria.novartis.com/newsroom/featured-news/2011-04-malaria-initiative-1.shtml. Accessed January 22, 2013.
  28. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW, , 2006. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum . J Infect Dis 193: 11511159. Available at: http://jid.oxfordjournals.org/content/193/8/1151.full.pdf. Accessed January 29, 2013.[Crossref]
  29. Haynes R, , 2009. Artemisinins: Remarkable Antimalarial Drugs, Usages, and Problems, and a New Derivative—Artemisone. United Nations Industrial Development Organization Seminar on Advanced Design and Development of Potential Drugs Against Malaria. Trieste, Italy: International Centre for Science and High Technology, AREA Science Park.
  30. Drugs for Neglected Diseases initiative. Articles. Available at: http://dndi.org/component/content/article/347-about-dndi/key-accomplishments/1212-malaria.html?highlight=YToyOntpOjA7czo0OiJhc2FxIjtpOjE7czo2OiJzYW5vZmkiO30=. Accessed January 1, 2013.
  31. Chatterjee DK, Venugopalan B, Lal B, de Souza NJ, Rupp RH, , 1988. Mélange de Médicaments pour la Prophylaxie et Thérapie de la Malaria. European patent no. EP 0290959. Munich, Germany: European Patent Office.
  32. Medecins Sans Frontieres, 2008. MSF Welcomes New Fixed-Dose Combination against Malaria. Available at: http://www.msf.org/article/msf-welcomes-new-fixed-dose-combination-against-malaria. Accessed January 2, 2013.
  33. Li G, Song J, , 2004. Composition Containing Artemisinin for Treatment of Malaria. U.S. patent no. US7851512. Washington, DC: U.S. Patent and Trademark Office.
  34. Access to Medicines Index, 2012. About the Index. Available at: http://www.accesstomedicineindex.org/. Accessed January 1, 2013.
  35. Hassoun N, , 2012. Measuring global health impact: incentivizing research and development of drugs for neglected diseases. Dev World Bioeth 12: 121134.[Crossref]
  36. Hassoun N, Lenard P, Straehle C, , 2012. Rating efforts to extend access on essential medicines: increasing global health impact. , eds. Health Inequalities and Global Justice. Edinburgh, United Kingdom: Edinburgh University Press, 176194.[Crossref]
  37. Hainmueller J, Hiscox MJ, Sequeira S, , 2014. Consumer Demand for the Fair Trade Label: Evidence from a Multi-Store Field Experiment. MIT Political Science Department Research Paper No. 2011-9B. Available at: http://dx.doi.org/10.2139/ssrn.1801942. Accessed August 1, 2014.
  38. Healthcare Packaging, 2012. Generic Drug Market to Grow to $221 Billion by 2016 News, May 1, 2012. Available at: http://www.healthcarepackaging.com/applications/healthcare/generic-drug-market-grow-221-billion-2016.
  39. Abdulrahman S, , 2014. Nigeria: private sector partners govt on fight against malaria. Daily Trust. Available at: http://allafrica.com/stories/201407161041.html. Accessed September 19, 2015.
  40. African Media and Malaria Research Network, 2013. Private sector in frontline attack. Eyes on Malaria Online. Available at: http://www.eyesonmalaria.org/content/private-sector-frontline-attack. Accessed September 19, 2015.
  41. Ghana News Agency, 2011. Business Community Urged to Help Fight Malaria. Available at: http://www.ghananewsagency.org/details/Health/Business-Community-urged-to-help-fight-malaria/?ci=1&ai=30705. Accessed September 19, 2015.
  42. WHO, 2015. Guidelines for the Treatment of Malaria. Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&ua=1. Accessed September 19, 2015.
  43. WHO, 2010. World Malaria Report 2010. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/malaria/publications/atoz/9789241564106/en/. Accessed September 26, 2015.
  44. Getnet G, Fola AA, Alemu A, Getie S, Fuehrer HP, Noedl H, , 2015. Therapeutic efficacy of artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. Malar J 14: 258.[Crossref]
  45. Bate R, Hess K, Mooney L, , 2010. Antimalarial medicine diversion: stock-outs and other public health problems. Res Rep Trop Med 1: 1924. Available at: https://www.aei.org/wp-content/uploads/2011/10/Antimalarial-drug-diversion-stock-outs-and-other-public-health-090210.pdf.[Crossref]
  46. Morris A, Ward A, Moonen B, Sabot O, Cohen JM, , 2015. Price subsidies increase the use of private sector ACTs: evidence from a systematic review. Health Policy Plan 30: 397405.[Crossref]
  47. Mikkelsen-Lopez I, Tediosi F, Abdallah G, Njozi M, Amuri B, Khatib R, Manzi F, de Savigny D, , 2013. Beyond antimalarial stock-outs: implications of health provider compliance on out-of-pocket expenditure during care-seeking for fever in south east Tanzania. BMC Health Serv Res 13: 444453.[Crossref]
  48. The maIERA Consultative Group on Health Systems and Operational Research, 2011. A research agenda for malaria eradication: health systems and operational research. PLoS Med 8: e1000397.[Crossref]
  49. Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M, , 2015. Effective coverage and systems effectiveness for malaria case management in sub-Saharan African countries. PLoS One 10: e0127818.[Crossref]
  50. Alonso PL, Tanner M, , 2013. Public health challenges and prospects for malaria control and elimination. Nat Med 19: 150155.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0409
Loading
/content/journals/10.4269/ajtmh.15-0409
Loading

Data & Media loading...

  • Received : 03 Jun 2015
  • Accepted : 10 Nov 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error